公开(公告)号：US20240307331A1

公开(公告)日：2024-09-19

申请号：US18173743

申请日：2021-08-23

Applicant: Abrexa Pharmaceuticals, Inc. ,  The Penn State Research Foundation

Inventor： Jesus E. VILLAFRANCA ,  Charles Richard KISSINGER ,  Guohong LI

IPC: A61K31/167 ,  A61K38/48 ,  A61P7/04 ,  A61P9/10

CPC classification number: A61K31/167 ,  A61K38/482 ,  A61P7/04 ,  A61P9/10 ,  C12Y304/21068

Abstract: Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies. Presented herein, in certain aspects, are methods for the treatment and/or prevention of hemorrhage and vascular instability that comprise administering a compound disclosed herein to a subject in need thereof.

公开(公告)号：US20240285655A1

公开(公告)日：2024-08-29

申请号：US18586450

申请日：2024-02-24

Applicant: PKZ, LLC

Inventor： J. Phillip Kennedy ,  Karyemaître Aliffe

IPC: A61K31/00 ,  A61K31/015 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/167 ,  A61K31/20 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4706 ,  A61K31/593 ,  A61K31/704 ,  A61K33/06 ,  A61K35/10 ,  A61K36/185 ,  A61K38/40 ,  A61K38/48

CPC classification number: A61K31/658 ,  A61K31/015 ,  A61K31/05 ,  A61K31/12 ,  A61K31/138 ,  A61K31/167 ,  A61K31/20 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4706 ,  A61K31/593 ,  A61K31/704 ,  A61K33/06 ,  A61K35/10 ,  A61K36/185 ,  A61K38/40 ,  A61K38/482

Abstract: Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

公开(公告)号：US20240271092A1

公开(公告)日：2024-08-15

申请号：US18510060

申请日：2023-11-15

Applicant: Emory University

Inventor： Edmund Waller ,  Anna Morris ,  Christopher Petersen ,  Jian-Ming Li ,  Reema Panjwani ,  Jingxia Li

IPC: C12N5/0783 ,  A61K35/17 ,  A61K35/28 ,  A61K38/20 ,  A61K38/22 ,  A61K38/48 ,  A61K38/54 ,  A61K39/39 ,  A61K45/06 ,  A61P31/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C12N5/0638 ,  A61K35/17 ,  A61K35/28 ,  A61K38/208 ,  A61K38/22 ,  A61K38/482 ,  A61K38/4886 ,  A61K38/54 ,  A61K39/39 ,  A61K45/06 ,  A61P31/00 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0636 ,  C12Y304/21039 ,  C12Y304/24011 ,  C12N2501/05 ,  C12N2501/51 ,  C12N2501/515

Abstract: This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

公开(公告)号：US20240207372A1

公开(公告)日：2024-06-27

申请号：US18361724

申请日：2023-07-28

Applicant: Thornhill Therapeutics, Inc.

Inventor： Randall J. Mrsny ,  Tahir Mahmood

IPC: A61K38/45 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K38/26 ,  A61K38/27 ,  A61K38/48 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/54 ,  C07K16/24

CPC classification number: A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.

公开(公告)号：US20240156922A1

公开(公告)日：2024-05-16

申请号：US18552254

申请日：2022-03-25

Applicant: Bio-Cat, Inc.

Inventor： Sean Michael GARVEY ,  Kelly Marie TINKER ,  Justin Lamont GUICE ,  Robert Daniel LITTLE ,  Christopher Edward SCHULER

IPC: A61K38/48 ,  A61P3/02

CPC classification number: A61K38/488 ,  A61K38/482 ,  A61K38/4886 ,  A61P3/02 ,  C12Y304/21063 ,  C12Y304/23018

Abstract: Fungal protease compositions, and more particularly, proteolytic enzyme mixtures comprising a plurality of Aspergillus proteases are provided. The disclosure also relates to protein hydrolysates, food and beverage products and dietary supplements produced using these proteolytic enzyme mixtures, and methods of making and using the same.

公开(公告)号：US11859208B2

公开(公告)日：2024-01-02

申请号：US16092068

申请日：2017-04-05

Applicant: Emory University

Inventor： Edmund Waller ,  Anna Morris ,  Christopher Petersen ,  Jian-Ming Li ,  Reema Panjwani ,  Jingxia Li

IPC: C12N5/0783 ,  A61K45/06 ,  A61K38/48 ,  A61K35/17 ,  A61P35/00 ,  A61K38/20 ,  A61K39/39 ,  A61P31/00 ,  A61K35/28 ,  A61K38/22 ,  A61K38/54 ,  C07K16/28

CPC classification number: C12N5/0638 ,  A61K35/17 ,  A61K35/28 ,  A61K38/208 ,  A61K38/22 ,  A61K38/482 ,  A61K38/4886 ,  A61K38/54 ,  A61K39/39 ,  A61K45/06 ,  A61P31/00 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0636 ,  C12Y304/21039 ,  C12Y304/24011 ,  C12N2501/05 ,  C12N2501/515

Abstract: This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.

公开(公告)号：US20230364094A1

公开(公告)日：2023-11-16

申请号：US18140128

申请日：2023-04-27

Applicant: CeleCor Therapeutics, Inc.

Inventor： Yatindra Joshi

IPC: A61K31/519 ,  A61K38/12 ,  A61K31/4365 ,  C07D513/04 ,  A61K38/48 ,  A61K31/37 ,  A61K31/702 ,  A61K31/4465 ,  A61K39/395 ,  A61K31/122 ,  A61K31/616 ,  A61K31/727

CPC classification number: A61K31/519 ,  A61K38/12 ,  A61K31/4365 ,  C07D513/04 ,  A61K38/482 ,  A61K31/37 ,  A61K31/702 ,  A61K31/4465 ,  A61K39/3955 ,  A61K31/122 ,  A61K31/616 ,  A61K31/727 ,  C07B2200/05

Abstract: Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

公开(公告)号：US20230285508A1

公开(公告)日：2023-09-14

申请号：US18198519

申请日：2023-05-17

Applicant: SynPhaGen LLC

Inventor： Todd Bernard Parsley ,  Christian Furlan Freguia

IPC: A61K38/20 ,  C02F3/34 ,  A61K38/45 ,  C12N15/113 ,  C12N15/86 ,  A61K38/48 ,  C12N15/11 ,  A61K48/00 ,  C12N15/70 ,  C12N7/00

CPC classification number: A61K38/2066 ,  C02F3/34 ,  A61K38/45 ,  C12N15/113 ,  C12N15/86 ,  C12Y203/02013 ,  A61K38/482 ,  C12N15/111 ,  A61K48/005 ,  C12N15/70 ,  C12N7/00 ,  C12Y201/02001 ,  C12N2310/14 ,  C12N2795/00031 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2795/00032 ,  C12N2795/00021 ,  C12N2820/55 ,  C12N2795/14143 ,  C12N2795/00043 ,  C12N2310/531

Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

公开(公告)号：US11752197B2

公开(公告)日：2023-09-12

申请号：US16990744

申请日：2020-08-11

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Julie Horowitz ,  Aris Baras ,  Manuel Allen Revez Ferreira

IPC: A61K38/18 ,  A61K38/17 ,  A61P1/00 ,  A61K31/12 ,  A61K31/4741 ,  A61K38/48 ,  C07K16/22 ,  C07K16/28 ,  C12Q1/6883 ,  G01N33/68 ,  G01N33/48 ,  G01N33/53 ,  C12Q1/6827 ,  C12Q1/68

CPC classification number: A61K38/18 ,  A61K31/12 ,  A61K31/4741 ,  A61K38/177 ,  A61K38/1709 ,  A61K38/1796 ,  A61K38/482 ,  A61K38/4846 ,  A61K38/4853 ,  A61P1/00 ,  C07K16/22 ,  C07K16/2863 ,  C12Q1/6883 ,  G01N33/6893 ,  C12Q1/68 ,  C12Q1/6827 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/48 ,  G01N33/53 ,  G01N2333/475 ,  G01N2333/71 ,  G01N2800/065

Abstract: Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.

公开(公告)号：US20230240988A1

公开(公告)日：2023-08-03

申请号：US18009485

申请日：2021-06-11

Applicant: The University of Birmingham

Inventor： Anthony Metcalfe ,  Richard Williams ,  Richard Moakes ,  Liam Grover

IPC: A61K9/06 ,  A61K31/7008 ,  A61K31/573 ,  A61K38/48 ,  A61K31/192 ,  A61K31/721 ,  A61K9/00

CPC classification number: A61K9/06 ,  A61K31/7008 ,  A61K31/573 ,  A61K38/482 ,  A61K31/192 ,  A61K31/721 ,  A61K9/0014 ,  A61K9/0048 ,  C12Y304/21064

Abstract: Disclosed are methods for forming shear-thinning fluid gel compositions comprising a microgel particle-forming polymer dispersed in an aqueous medium. The viscosity of the fluid gel compositions reduces when the gel is exposed to shear. Also disclosed are shear-thinning fluid gel compositions obtained by such methods, and medical uses of such compositions.